{"id":818492,"date":"2026-07-23T10:03:21","date_gmt":"2026-07-23T10:03:21","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/818492\/"},"modified":"2026-07-23T10:03:21","modified_gmt":"2026-07-23T10:03:21","slug":"nhl-car-t-therapy-market-reaches-3-2b","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/818492\/","title":{"rendered":"NHL CAR-T therapy market reaches $3.2b"},"content":{"rendered":"<p>Market reached $3.2b in 2025, with the US accounting for 59% of total value.<\/p>\n<p>The <a href=\"https:\/\/healthcareasiamagazine.com\/healthcare\/news\/kauvery-hospital-launches-car-t-cell-therapy-blood-cancers\" target=\"_blank\" rel=\"noopener dofollow\">CAR-T cell therapy<\/a> market for non-Hodgkin lymphoma (NHL) reached $3.2b across the seven major markets (7MM) in 2025, according to DelveInsight.<\/p>\n<p>The 7MM consists of the US, EU4\u2013which as Germany, France, Italy, and Spain\u2013the UK, and Japan. The US alone accounted for 59% of total market size.<\/p>\n<p>The market is projected to grow at a compound annual growth rate of about 7% from 2026 to 2036, supported by wider clinical adoption, expanding treatment indications, and new therapies entering the market.<\/p>\n<p>\u201cThe entry of emerging and late-stage CAR T-cell therapies is expected to intensify competition in the CAR T-cell therapy landscape for NHL during the forecast period,\u201d said Aparna Thakur, Project Manager of Forecasting at DelveInsight.<\/p>\n<p>Growth is being driven by demand for treatments for relapsed or refractory NHL, particularly aggressive subtypes such as diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.\u00a0<\/p>\n<p>CAR-T therapies are also seeing broader use in earlier treatment settings and across additional lymphoma subtypes.<\/p>\n<p>Approved therapies such as TECARTUS, BREYANZI, KYMRIAH, and YESCARTA are competing alongside pipeline candidates under development.<\/p>\n<p>Drugmakers are developing next-generation CAR-T platforms, including allogeneic therapies aimed at broadening patient access and in vivo CAR-T approaches that generate CAR-T cells inside the patient\u2019s body after infusion.<\/p>\n<p>Across the 7MM, selected CAR-T indications in NHL recorded about 159,000 incident cases in 2025. DLBCL accounted for the largest number of incident cases at about 78,000.<\/p>\n","protected":false},"excerpt":{"rendered":"Market reached $3.2b in 2025, with the US accounting for 59% of total value. The CAR-T cell therapy&hellip;\n","protected":false},"author":2,"featured_media":818493,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[556],"tags":[64,63,575,85],"class_list":["post-818492","post","type-post","status-publish","format-standard","has-post-thumbnail","category-nhl","tag-au","tag-australia","tag-nhl","tag-sports"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/818492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=818492"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/818492\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/818493"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=818492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=818492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=818492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}